Vertigo Treatment Market Research Report - Forecast till 2027

Vertigo Treatment Market Research Report: By Type (BPPV, Labyrinthitis, Vestibular Neuronitis, Meniere’s disease), By Treatment (Anticholinergics, Antihistamines, Benzodiazepines, Others) and By End-User (Hospital, Clinics)-Forecast to 2027

ID: MRFR/HC/6986-HCR | August 2022 | Region: Global | 100 Pages         

Table of Contents

1. EXECUTIVE SUMMARY

1.1. Market Attractiveness Analysis

1.1.1. Global Vertigo Treatment Market, by Type

1.1.2. Global Vertigo Treatment Market, by Treatment

1.1.3. Global Vertigo Treatment Market, by End User

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.5. Breakdown of Primary Respondents

3.6. Forecasting Techniques

3.7. Research Methodology for Market Size Estimation

3.8. Bottom-Up Approach

3.9. Top-Down Approach

3.10. Data Triangulation

3.11. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

5.2.1. R&D and Designing

5.2.2. Manufacturing

5.2.3. Distribution & Sales

5.2.4. Post Sales Services

6. GLOBAL VERTIGO TREATMENT MARKET, BY TYPE

6.1. Overview

6.2. Benign paroxysmal positional vertigo (BPPV)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3. Labyrinthitis

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4. Vestibular neuronitis

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.5. Meniere’s disease

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7. GLOBAL VERTIGO TREATMENT MARKET, BY TREATMENT

7.1. Overview

7.2. Anticholinergics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3. Antihistamines

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4. Benzodiazepines

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.5. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8. GLOBAL VERTIGO TREATMENT MARKET, BY END USER

8.1. Overview

8.2. Hospital

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3. Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.4. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9. GLOBAL VERTIGO TREATMENT MARKET, BY REGION

9.1. Overview

9.2. Americas

9.2.1. North America

9.2.1.1. US

9.2.1.2. Canada

9.2.2. Latin America

9.3. Europe

9.3.1. Western Europe

9.3.1.1. Germany

9.3.1.2. France

9.3.1.3. Italy

9.3.1.4. Spain

9.3.1.5. UK

9.3.1.6. Rest of Western Europe

9.3.2. Eastern Europe

9.4. Asia-Pacific

9.4.1. Japan

9.4.2. China

9.4.3. India

9.4.4. Australia

9.4.5. South Korea

9.4.6. Rest of Asia-Pacific

9.5. Middle East & Africa

9.5.1. Middle East

9.5.2. Africa

10. COMPANY LANDSCAPE

10.1. Overview

10.2. Competitor Dashboard

10.3. Major Growth Strategy in the Global Vertigo Treatment Market

10.4. Competitive Benchmarking

10.5. The Leading Player in terms of Number of Developments in the Global Vertigo Treatment Market

10.6. Key Developments & Growth Strategies

10.7. Major Players Financial Matrix & Market Ratio

11. COMPANY PROFILES

11.1. F. Hoffmann-La Roche

11.1.1. Company Overview

11.1.2. Drugs/Services Offered

11.1.3. Financial Overview

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. GlaxoSmithKline

11.3. Novartis

11.4. Pfizer

11.5. Teva Pharmaceutical

11.6. Sanofi

11.7. AstraZeneca

11.8. Intas Pharmaceutical Ltd

11.9. Sun Pharmaceutical Industries Ltd

11.10. Others

12. APPENDIX

12.1. References

12.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL VERTIGO TREATMENT MARKET SYNOPSIS, 2020-2027

TABLE 2 GLOBAL VERTIGO TREATMENT MARKET ESTIMATES & FORECAST, 2020-2027(USD MILLION)

TABLE 3 GLOBAL VERTIGO TREATMENT MARKET, BY TYPE, 2020-2027(USD MILLION)

TABLE 4 GLOBAL VERTIGO TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)

TABLE 5 GLOBAL VERTIGO TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 6 GLOBAL VERTIGO TREATMENT MARKET, BY REGION, 2020-2027(USD MILLION)

TABLE 7 NORTH AMERICA: VERTIGO TREATMENT MARKET, BY TYPE, 2020-2027(USD MILLION)

TABLE 8 NORTH AMERICA: VERTIGO TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)

TABLE 9 NORTH AMERICA: VERTIGO TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 10 US: VERTIGO TREATMENT MARKET, BY TYPE, 2020-2027(USD MILLION)

TABLE 11 US: VERTIGO TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)

TABLE 12 US: VERTIGO TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 13 CANADA: VERTIGO TREATMENT MARKET, BY TYPE, 2020-2027(USD MILLION)

TABLE 14 CANADA: VERTIGO TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)

TABLE 15 CANADA: VERTIGO TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 16 LATIN AMERICA: VERTIGO TREATMENT MARKET, BY TYPE, 2020-2027(USD MILLION)

TABLE 17 LATIN AMERICA: VERTIGO TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)

TABLE 18 LATIN AMERICA: VERTIGO TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 19 EUROPE: VERTIGO TREATMENT MARKET, BY TYPE, 2020-2027(USD MILLION)

TABLE 20 EUROPE: VERTIGO TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)

TABLE 21 EUROPE: VERTIGO TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 22 WESTERN EUROPE: VERTIGO TREATMENT MARKET, BY TYPE, 2020-2027(USD MILLION)

TABLE 23 WESTERN EUROPE: VERTIGO TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)

TABLE 24 WESTERN EUROPE: VERTIGO TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 25 EASTERN EUROPE: VERTIGO TREATMENT MARKET, BY TYPE, 2020-2027(USD MILLION)

TABLE 26 EASTERN EUROPE: VERTIGO TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)

TABLE 27 EASTERN EUROPE: VERTIGO TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 28 ASIA-PACIFIC: VERTIGO TREATMENT MARKET, BY TYPE, 2020-2027(USD MILLION)

TABLE 29 ASIA-PACIFIC: VERTIGO TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)

TABLE 30 ASIA-PACIFIC: VERTIGO TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA: VERTIGO TREATMENT MARKET, BY TYPE, 2020-2027(USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA: VERTIGO TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA: VERTIGO TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)


LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL VERTIGO TREATMENT MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL VERTIGO TREATMENT MARKET

FIGURE 4 GLOBAL VERTIGO TREATMENT MARKET SHARE, BY TYPE, 2020 (%)

FIGURE 5 GLOBAL VERTIGO TREATMENT MARKET SHARE, BY TREATMENT, 2020 (%)

FIGURE 6 GLOBAL VERTIGO TREATMENT MARKET SHARE, BY END USER, 2020 (%)

FIGURE 7 GLOBAL VERTIGO TREATMENT MARKET SHARE, BY ROUTE OF ADMINISTRATION, 2020 (%)

FIGURE 8 GLOBAL VERTIGO TREATMENT MARKET SHARE, BY REGION, 2020 (%)

FIGURE 9 AMERICAS: VERTIGO TREATMENT MARKET SHARE BY REGION, 2020 (%)

FIGURE 10 NORTH AMERICA: VERTIGO TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 11 EUROPE: VERTIGO TREATMENT MARKET SHARE, BY REGION, 2020 (%)

FIGURE 12 WESTERN EUROPE: VERTIGO TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 13 ASIA-PACIFIC: VERTIGO TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 14 MIDDLE EAST & AFRICA: VERTIGO TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 15 GLOBAL VERTIGO TREATMENT MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 16 F. HOFFMANN-LA ROCHE: KEY FINANCIALS

FIGURE 17 F. HOFFMANN-LA ROCHE SEGMENTAL REVENUE

FIGURE 18 F. HOFFMANN-LA ROCHE: REGIONAL REVENUE

FIGURE 19 GLAXOSMITHKLINE: KEY FINANCIALS

FIGURE 20 GLAXOSMITHKLINE: SEGMENTAL REVENUE

FIGURE 21 GLAXOSMITHKLINE: REGIONAL REVENUE

FIGURE 22 NOVARTIS: KEY FINANCIALS

FIGURE 23 NOVARTIS: SEGMENTAL REVENUE

FIGURE 24 NOVARTIS: REGIONAL REVENUE

FIGURE 25 PFIZER: KEY FINANCIALS

FIGURE 26 PFIZER: SEGMENTAL REVENUE

FIGURE 27 PFIZER.: REGIONAL REVENUE

FIGURE 28 TEVA PHARMACEUTICAL: KEY FINANCIALS

FIGURE 29 TEVA PHARMACEUTICAL: SEGMENTAL REVENUE

FIGURE 30 TEVA PHARMACEUTICAL: REGIONAL REVENUE

FIGURE 31 ASTRAZENECA: KEY FINANCIALS

FIGURE 32 ASTRAZENECA: SEGMENTAL REVENUE

FIGURE 33 ASTRAZENECA: REGIONAL REVENUE

FIGURE 34 SANOFI: KEY FINANCIALS

FIGURE 35 SANOFI: SEGMENTAL REVENUE

FIGURE 36 SANOFI: REGIONAL REVENUE

FIGURE 37 SUN PHARMACEUTICAL INDUSTRIES: KEY FINANCIALS

FIGURE 38 SUN PHARMACEUTICAL INDUSTRIES: SEGMENTAL REVENUE

FIGURE 39 SUN PHARMACEUTICAL INDUSTRIES: REGIONAL REVENUE


Vertigo Treatment Market

Vertigo Treatment Market accounted for USD 1,800 Million at a CAGR of 4.2% during forecast period

Segmentation

By Type Bppv Labyrinthitis Vestibular Neuronitis Meniere&Rsquo Disease
By Treatment Anticholinergics Antihistamines Benzodiazepines Others
By End-User Hospital Clinics

Key Players

  • Hoffmann-La Roche (Switzerland)
  • GlaxoSmithKline (UK)
  • Novartis (Switzerland)
  • Pfizer (US)
  • Teva Pharmaceutical (Israel)
  • Sanofi (France)
  • AstraZeneca (UK)
  • Intas Pharmaceutical Ltd (India)
  • Sun Pharmaceutical Industries Ltd (India)

Drivers

  • Increase in prevalence of vertigo cases
  • Rise in healthcare expenditure
  • Increasing geriatric population
Speak to Analyst Request a Free Sample

Vertigo Treatment Market Forecast


Vertigo Treatment Market accounted for USD 1,800 Million in 2018 at a CAGR of 4.2%.


Market Synopsis


Vertigo is a sense of spinning dizziness that can be caused by problems in the brain or inner ear, including sudden head movements, or inflammation in the inner ear due to a viral or bacterial infection. Vertigo can be treated with medications such as steroids that can reduce internal ear inflammation, and water pills that can reduce fluid buildup in the ear.


Vertigo Treatment Market Influencer


The increasing initiatives by public and private companies influence the market growth positively. The ever-increasing number of clearances and product launches by key players in the market are likely to act as a promising factor for the vertigo teatment market growth in the near future.


Vertigo Treatment Market Drivers



  • Increase in prevalence of vertigo cases

    • Cases of vertigo are on the rise, with over 20% 50% of the global population affected by vertigo and According to the National Center for Biotechnology Information, in the US, around 26 million people required a visit to an emergency department for dizziness/vertigo.



  • Rapid technological advancements

  • Rise in healthcare expenditure

  • Increasing geriatric population

  • Increasing mergers & acquisitions by prominent players in the vertigo treatment market

  • Growing initiatives to create awareness

    • For instance, the German Center for Vertigo and Balance Disorders (DSGZ) started an initiative called DIZZYNET. The main aim is to create a platform for collaboration and exchange among scientists, physicians, and physiotherapists to understand the treatment options and epidemiology of vertigo. Such initiates help to create awareness regarding symptoms and treatment for vertigo.




Vertigo Treatment Market Restraints



  • Lack of information about the symptoms and causes of vertigo


Vertigo Treatment Market Segmentation


By Type




  • Benign Paroxysmal Positional Vertigo (BPPV): Expected to hold the largest share, as benign paroxysmal positional vertigo is the most common form of peripheral vertigo. This type tends to cause short, frequent bouts of vertigo.




  • Labyrinthitis: An inner ear infection causes labyrinthitis form of vertigo. This form of vertigo is usually overlooked as they appear with other symptoms such as fever and earache.




  • Vestibular Neuronitis: Vestibular neuritis is a disorder that affects the nerve of the inner ear. This type of vertigo has a sudden onset and may cause unsteadiness, earache, nausea, and vomiting.




  • Meniere’s disease: This type of vertigo is often so severe that it causes nausea and vomiting. Meniere’s disease also causes hearing loss, ringing in your ears, and a feeling of fullness in your ears.




By Treatment




  • Anticholinergics: Anticholinergics are vestibular suppressants and are most important in treating vertigo since anticholinergic drugs that do not cross the blood-brain barrier are ineffective in controlling motion sickness. The most effective single anticholinergic drug for the prophylaxis and treatment of motion sickness is scopolamine. All anticholinergics conventionally used in the management of vertigo or motion sickness have prominent side-effects, often including dry mouth, dilated pupils, and sedation. Anticholinergics are ineffective if administered after symptoms have already appeared.




  • Antihistamines: Centrally acting antihistamines prevent motion sickness and reduce the severity of symptoms, even if taken after the onset of the symptoms. All the antihistamines in general use for control of vertigo also have anticholinergic activity.




  • Benzodiazepines: Benzodiazepines are extremely useful for the management of acute vertigo. They are also helpful in controlling motion sickness and can also minimize anxiety and panic associated with vertigo. Diazepam, clonazepam, lorazepam, and alprazolam are commonly prescribed benzodiazepines for their effect as anxiolytics and antidepressants.




  • Others: The other segment includes antibiotics and other drugs that can help ease the symptoms of vertigo.




By End-User




  • Hospital: Hospitals dominate the global market for vertigo treatment. The positive growth of hospitals is attributed to their rising need to offer treatments for various health disorders. Additionally, the large number of hospitals is also driving the growth for the hospital's segment.




  • Clinics: Clinics take up the second-largest share due to the rising number of clinics and the increasing patient population.




Vertigo Treatment Market By Region




  • Americas: It is the largest regional vertigo treatment market owing to the large patient population, rise in prevalence of vertigo, and surge in awareness about the causes of vertigo and its treatments. According to the American Speech-Language-Hearing Association, around 40% of the population in the US experience some form of dizziness or balance difficulty over the course of a lifetime.




  • Europe: The growing presence of the developed pharmaceutical industry and the significant demand for vertigo related therapeutics is driving the growth of the vertigo treatment market in Europe. According to the National Center for Biotechnology Information, the prevalence of vertigo in Germany was 22.9%.




  • Asia-Pacific: The Asia-Pacific region is anticipated to be the fastest-growing region in the global vertigo treatment market. This region has witnessed a surge in the number of people afflicted with vertigo and other neurological disorders.




  • Middle East & Africa: The smallest market due to limited healthcare infrastructure and limited exposure to technological advancements.




Vertigo Treatment Market Key Players



  • Hoffmann-La Roche (Switzerland)

  • GlaxoSmithKline (UK)

  • Novartis (Switzerland)

  • Pfizer (US)

  • Teva Pharmaceutical (Israel)

  • Sanofi (France)

  • AstraZeneca (UK)

  • Intas Pharmaceutical Ltd (India)

  • Sun Pharmaceutical Industries Ltd (India)



Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

vertigo treatment market is projected grow at approximately 4.2% CAGR during the assessment period (2019-2025).

The valuation of the global vertigo treatment market had reached 1,800 MN in 2018.

By type, the benign paroxysmal positional vertigo (BPPV) segment, by treatment, the anticholinergics segment, and end user, the hospital segment holds the majority shares in the global vertigo treatment market.

North America holds the largest share in the global vertigo treatment market, followed by Europe and the Asia Pacific, respectively.

GlaxoSmithKline (UK), F. Hoffmann-La Roche (Switzerland), Novartis (Switzerland), Teva Pharmaceutical (Israel), Pfizer (US), Sanofi (France), Intas Pharmaceutical Ltd (India), AstraZeneca (UK), and Sun Pharmaceutical Industries Ltd (India), are some of the major players operating in the global vertigo treatment market.